Results from the first phase III clinical trial evaluating the addition of the anti-VEGF MoAb bevacizumab to 5-fluorouracil and irinotecan represented the beginning of a new era for mCRC treatment by showing that such combined treatment could result into a significant improvement in tumor objective response (OR), progression-free survival (PFS), and OS [7]. The gene discussed is VEGFA; the disease is neoplasm.